CLEC9A and neoplasm: With respect to cancer immunotherapy, the potential of antigen targeting to different endocytic receptors, including DEC205, DCIR2, CLEC9A, CD36, LOX-1, CD11c, and MHC-II was proven in several murine tumor models [133,137,138,694,695,698,699,700,701,702,703,704,705,706].